Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Chen

Showing results (141-150 of 146) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 146 results.
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
International Journal of Molecular Sciences|August 29, 2018
Therapeutic Immunization against GlioblastomaVirgil E J C Schijns, Chrystel Pretto, Anna M Strik, et al.
Physical Therapy|September 26, 2009
An intensive, progressive exercise program reduces disability and improves functional performance in patients after single-level lumbar microdiskectomyKornelia Kulig, George J Beneck, David M Selkowitz, et al.
Nature|September 17, 2015
Nanoparticle biointerfacing by platelet membrane cloakingChe-Ming J Hu, Ronnie H Fang, Kuei-Chun Wang, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
Pageof 15

Showing results (141-150 of 146) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 146 results.
Frontiers in Oncology|July 15, 2022
A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and TemozolomideDaniela A Bota, Thomas H Taylor, Naomi Lomeli, et al.
International Journal of Molecular Sciences|August 29, 2018
Therapeutic Immunization against GlioblastomaVirgil E J C Schijns, Chrystel Pretto, Anna M Strik, et al.
Physical Therapy|September 26, 2009
An intensive, progressive exercise program reduces disability and improves functional performance in patients after single-level lumbar microdiskectomyKornelia Kulig, George J Beneck, David M Selkowitz, et al.
Nature|September 17, 2015
Nanoparticle biointerfacing by platelet membrane cloakingChe-Ming J Hu, Ronnie H Fang, Kuei-Chun Wang, et al.
JAMA Oncology|February 3, 2018
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical TrialMartin J B Taphoorn, Linda Dirven, Andrew A Kanner, et al.
JAMA|December 17, 2015
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical TrialRoger Stupp, Sophie Taillibert, Andrew A Kanner, et al.
Pageof 15